(INMD) InMode Ltd. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(INMD) InMode Ltd. Complete Analysis Pack
Download Your Competitive Advantage
This InMode Ltd. BCG Matrix shows how the company’s products or business units may be positioned across Stars, Cash Cows, Question Marks, and Dogs, making it useful for strategy, portfolio review, and investment analysis. The page already includes a real preview of the actual report content, so you can see what the analysis looks like before buying. Purchase the full version to get the complete ready-to-use matrix.
Stars
Morpheus8 RF microneedling
Morpheus8 RF microneedling is InMode Ltd.'s flagship non-surgical skin remodeling platform, used for tightening and resurfacing with strong clinic adoption. It sits in a growing aesthetic medicine category, where demand for minimally invasive skin rejuvenation keeps rising. Its strong brand pull and wide practitioner use support Star status in the BCG Matrix.
Morpheus8 Body
Morpheus8 Body is InMode Ltd.'s body-focused extension of the Morpheus8 franchise, built for larger zones like the abdomen, arms, and thighs. It fits the Stars label because demand for body contouring remains strong, and the broader Morpheus8 platform keeps driving high-growth adoption across aesthetic practices.
Morpheus8 Burst
Morpheus8 Burst is a newer upgrade of Morpheus8 with improved treatment delivery, so it fits a fast refresh cycle rather than a mature cash-cow stage. InMode can scale it through clinician training and upgrades across its installed base, which supports repeat sales without waiting for new-account wins. If adoption stays strong, it can keep Star-like growth traits in a high-demand aesthetic market.
EmpowerRF platform
EmpowerRF is a Star in InMode Ltd.’s BCG mix: it targets women’s health and pelvic wellness, a fast-growing procedural niche with repeat clinic use. Its multi-applicator platform helps sell one system into several revenue streams, which supports scale and sticky adoption. The category’s recurring demand can keep utilization high once clinics add it.
- Women’s health and pelvic care focus
- Recurring clinic demand supports usage
- Multi-applicator model boosts scale
- Best fit for growth-led capital spend
Aviva
Aviva is InMode Ltd.’s minimally invasive women’s health offering, aimed at outpatient aesthetic gynecology. It fits the move toward office-based care, where shorter recovery and lower procedure time support adoption. As a newer category, it still has room to scale as demand rises for non-surgical intimate health treatments.
- Minimally invasive women’s health
- Outpatient care drives demand
- Newer category, high growth runway
InMode’s Star Products Power High-Growth Demand
InMode Ltd.’s Stars are Morpheus8, Morpheus8 Body, Morpheus8 Burst, EmpowerRF, and Aviva. These platforms sit in high-growth segments like non-surgical skin remodeling, body contouring, and women’s health, where clinic adoption and repeat use can support scale. Their mix of strong demand and room to expand fits the BCG Star profile.
| Product | Star driver |
|---|---|
| Morpheus8 | Flagship demand |
| EmpowerRF | Recurring use |
What is included in the product
Detailed Word Document
InMode Ltd. BCG Matrix pinpoints which products to invest in, hold, or divest across Stars, Cash Cows, Question Marks, and Dogs.
Editable Excel File
InMode Ltd. BCG Matrix at a glance, pinpointing each unit’s role for faster, clearer strategy decisions.
Reference Sources
Provides a credible source trail for InMode Ltd. that supports fast validation, stronger due diligence, and better decision-making.
Cash Cows
BodyTite RFAL
BodyTite RFAL is InMode Ltd.'s mature radiofrequency-assisted lipolysis line, with a long commercial run and strong name recognition in minimally invasive body contouring. Its installed base keeps consumables, service, and repeat procedure demand steady, which makes it a classic cash cow. InMode ended 2024 with $394.4 million in cash and marketable securities and no debt, giving this line strong cash support.
FaceTite RFAL
FaceTite RFAL is InMode Ltd.’s well-known facial tightening and contouring device, aimed at a mature aesthetic surgery niche with repeat provider use. Its lower growth profile but steady procedure demand makes it a Cash Cow, especially as InMode generated about $395 million in revenue in FY2024 and maintained strong profitability. That mix of established demand and solid monetization supports ongoing cash flow even if category growth slows.
AccuTite RFAL
AccuTite RFAL is a small-area radiofrequency-assisted lipolysis system for precise facial and body zones, so it fits a Cash Cow profile: established, commercialized, and still monetizing a stable practitioner base. InMode's mature platform strategy supports this kind of repeat-use demand, not early-stage adoption.
Lumecca IPL
Lumecca IPL is InMode Ltd.’s IPL-based skin revitalization line, and it fits a Cash Cow profile because the light-based aesthetics market is mature and crowded. With a large installed base and repeat consumable-style use, it can still generate steady cash even as growth slows.
- Mature, highly competitive IPL market
- Installed base supports repeat use
- Cash flow stays strong, growth softer
DiolazeXL laser hair removal
DiolazeXL sits in a large, crowded hair-removal market where demand stays steady but growth is slower than in newer aesthetic segments. That makes it a Cash Cow for InMode Ltd. because clinics can keep using it for recurring procedural volume, even if the category is no longer a fast-expanding story.
The device fits a mature product profile: proven use case, broad customer demand, and repeat visits that help support cash flow with limited reinvestment. In BCG terms, that is exactly the kind of asset that can fund newer growth bets while still delivering reliable revenue.
- Large market, but mature growth
- Steady procedure demand supports volume
- Recurring clinic use drives cash flow
- Funds InMode Ltd. growth products
InMode’s Cash Cows: Steady Sales, Strong Cash, Zero Debt
InMode Ltd.’s Cash Cows are BodyTite RFAL, FaceTite RFAL, AccuTite RFAL, Lumecca IPL, and DiolazeXL: mature lines with wide installed bases, repeat clinic use, and slower growth than newer launches. InMode ended FY2024 with $394.4 million in cash and marketable securities and no debt, so these products can keep producing cash with low balance-sheet risk.
| Product | Cash cow driver |
|---|---|
| BodyTite RFAL | Installed base, repeat demand |
| Lumecca IPL | Mature market, steady use |
| DiolazeXL | Recurring clinic volume |
Full Version Awaits
InMode Ltd. Reference Sources
The InMode Ltd. BCG Matrix preview you see here is the exact same document you’ll receive after purchase. No demo pages, no placeholders—just the full, professional analysis file ready for immediate use. Once purchased, you’ll get the complete version instantly for review, printing, or presentation. What you preview is what you own.
Dogs
Evolve body contouring
Evolve body contouring sits in a crowded hands-free body shaping niche, and competition is intense. It does not have the same clear differentiation as InMode Ltd.'s core RF franchises, so pricing power and share gains are harder to sustain. With low growth and weaker relative share, it fits the Dog bucket in the BCG Matrix.
Contoura body sculpting
Contoura body sculpting is a Dog in InMode Ltd.'s BCG Matrix: it sits in a mature body-contouring niche with low growth. The line faces heavy pressure from med-spa and energy-based rivals, so pricing and share gains are hard to defend. With limited strategic upside, it deserves lower capital priority than faster-growing platforms.
Votiva women’s wellness
Votiva women’s wellness fits the Dogs bucket. It is an older platform with a real market, but newer and broader systems have pulled attention away, so growth has slowed and its BCG position has weakened. For InMode Ltd., that points to limited upside and a lower priority for fresh capital versus higher-growth products.
FormaV vaginal remodeling
FormaV looks like a Dog in InMode Ltd.'s BCG mix: it is an adjunct women’s health handpiece with limited differentiation, while RF and laser rivals keep crowding the niche. InMode reported 2025 revenue of about $360M and still leaned on broader platform sales, which fits a low-share, mature submarket where FormaV likely adds little growth.
- Limited product edge
- Crowded RF and laser field
- Low share, mature niche
- Dog status fits
Triton multi-technology hair removal
Triton is a multi-wavelength hair-removal system in a crowded category where price cuts and channel pressure are common. InMode’s own filings showed 2025 revenue concentration still leaned on core aesthetics, so Triton must win share in a market where no clear moat exists. If adoption is not dominant, it fits BCG "Dog" logic: low relative share, modest growth, and weak pricing power.
- Multi-wavelength, but not a clear leader.
- Hair removal is big; margins are tight.
- Competition keeps pricing under pressure.
InMode’s Dog Products Lag in Crowded, Low-Margin Markets
InMode Ltd.'s Dogs, including Evolve, Contoura, Votiva, FormaV, and Triton, sit in crowded, low-growth niches with weak differentiation and tight pricing power. In 2025, InMode Ltd. reported about $360M in revenue, but these lines likely added little relative share or margin lift. That makes them low-priority for new capital.
| Product | BCG | Signal |
|---|---|---|
| Evolve | Dog | Low share |
| Triton | Dog | Crowded market |
Question Marks
QuantumRF 10
QuantumRF 10 is InMode Ltd.'s newer fractional RF platform for minimally invasive tightening. The market looks attractive, but adoption is still scaling, so share is not yet proven. That mix of high growth potential and uncertain penetration makes it a Question Mark.
QuantumRF 25
QuantumRF 25 is the higher-power QuantumRF setup, aimed at deeper treatment zones, so it can widen InMode Ltd.'s reach in energy-based aesthetics. It sits in an upgrade cycle where adoption can still grow, but its current share is not yet clear, which is why it fits Question Mark status. InMode's 2025 scale makes this a meaningful bet, but the product still needs proof of demand and repeat pull-through.
IgniteRF
IgniteRF fits the Question Mark in InMode Ltd.'s BCG Matrix: it is a next-generation RF platform for precision energy delivery, but commercial penetration is still early. The aesthetics energy device market is still expanding, so the upside is real, yet IgniteRF needs more sales push and product investment to build share. Until adoption scales, it will likely absorb cash more than it returns.
EvolveX hands-free sculpting
EvolveX hands-free sculpting fits Question Mark in InMode Ltd.’s BCG Matrix: it is a newer body-sculpting platform in a growing aesthetic-market niche, but its share is still not clearly proven against crowded rivals. InMode’s latest public filings do not break out EvolveX revenue, so traction is harder to verify.
- Growing category, but crowded field
- Share not yet proven
- Needs clear adoption data
MorpheusV women’s health
MorpheusV women’s health fits a Question Mark in InMode Ltd.’s BCG Matrix: it uses RF microneedling for women’s health, sits in a growing addressable market, but still has low share and an early rollout profile. Its upside is real if adoption scales, yet the business case depends on proof of demand, reimbursement, and clinic uptake. High growth potential, but not a proven cash engine yet.
- Growing market, early-stage product
- Low share, high execution risk
- Upside depends on rollout speed
Question Mark Products: Big Potential, Unproven Traction
QuantumRF 10, QuantumRF 25, IgniteRF, EvolveX, and MorpheusV women’s health are Question Marks because they sit in growing aesthetic niches, but InMode Ltd. has not shown clear share by product. The latest filings also do not break out product revenue, so traction is hard to verify. That makes each one a bet on adoption, not a proven cash driver.
| Product | BCG fit | Key signal |
|---|---|---|
| QuantumRF 10 | Question Mark | Newer platform, share unproven |
| EvolveX | Question Mark | Growing niche, no revenue split |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.